Management of Vascular Calcification in Hemodialysis: Efforts in Vain or Promising Strategies?

References

1. McCullough P.A. Sandberg K.R. Dumler F. Yanez J.E. Determinants of coronary vascular calcification in patients with chronic kidney disease and end-stage renal disease: A systematic review. J. Nephrol. 2004 17 2 205 215 15293519
   [Google Scholar]
2. Ketteler M. Block G.A. Evenepoel P. Executive summary of the 2017 KDIGO Chronic Kidney Disease–Mineral and Bone Disorder (CKD-MBD) Guideline Update: What’s changed and why it matters. Kidney Int. 2017 92 1 26 36 10.1016/j.kint.2017.04.006 28646995
   [Google Scholar]
3. Drüeke T. Primary and secondary uraemic hyperparathyroidism: From initial clinical observations to recent findings. Nephrol. Dial. Transplant. 1998 13 6 1384 1387 10.1093/ndt/13.6.1384 9641165
   [Google Scholar]
4. Moe S.M. Calcium as a cardiovascular toxin in CKD-MBD. Bone 2017 100 94 99 10.1016/j.bone.2016.08.022 27576942
   [Google Scholar]
5. Evenepoel P. Jørgensen H.S. Bover J. Recommended calcium intake in adults and children with chronic kidney disease—a European consensus statement. Nephrol. Dial. Transplant. 2024 39 2 341 366 10.1093/ndt/gfad185 37697718
   [Google Scholar]
6. Chertow G.M. Burke S.K. Raggi P. Sevelamer attenuates the progression of coronary and aortic calcification in hemodialysis patients. Kidney Int. 2002 62 1 245 252 10.1046/j.1523‑1755.2002.00434.x 12081584
   [Google Scholar]
7. Qunibi W. Moustafa M. Muenz L.R. A 1-year randomized trial of calcium acetate versus sevelamer on progression of coronary artery calcification in hemodialysis patients with comparable lipid control: The Calcium Acetate Renagel Evaluation-2 (CARE-2) study. Am. J. Kidney Dis. 2008 51 6 952 965 10.1053/j.ajkd.2008.02.298 18423809
   [Google Scholar]
8. Neradova A. Schumacher S.P. Hubeek I. Lux P. Schurgers L.J. Vervloet M.G. Phosphate binders affect vitamin K concentration by undesired binding, an in vitro study. BMC Nephrol. 2017 18 1 149 10.1186/s12882‑017‑0560‑3 28464802
   [Google Scholar]
9. Xu J.P. Zeng R.X. Liao P.D. Zhang M.Z. Effect of lanthanum carbonate on the progression of coronary artery calcification in hemodialysis patients: A meta‐analysis of randomized controlled trials. Hemodial. Int. 2022 26 2 223 233 10.1111/hdi.12988 34897963
   [Google Scholar]
10. Bover J. Ureña P. Brandenburg V. Adynamic bone disease: From bone to vessels in chronic kidney disease. Semin. Nephrol. 2014 34 6 626 640 10.1016/j.semnephrol.2014.09.008 25498381
    [Google Scholar]
11. Terai K. Nara H. Takakura K. Vascular calcification and secondary hyperparathyroidism of severe chronic kidney disease and its relation to serum phosphate and calcium levels. Br. J. Pharmacol. 2009 156 8 1267 1278 10.1111/j.1476‑5381.2008.00108.x 19302594
    [Google Scholar]
12. Eifinger F. Wahn F. Querfeld U. Coronary artery calcifications in children and young adults treated with renal replacement therapy. Nephrol. Dial. Transplant. 2000 15 11 1892 1894 10.1093/ndt/15.11.1892 11071992
    [Google Scholar]
13. Ishimura E. Okuno S. Kitatani K. Significant association between the presence of peripheral vascular calcification and lower serum magnesium in hemodialysis patients. Clin. Nephrol. 2007 68 10 222 227 10.5414/CNP68222 17969489
    [Google Scholar]
14. London G.M. Marty C. Marchais S.J. Guerin A.P. Metivier F. de Vernejoul M.C. Arterial calcifications and bone histomorphometry in end-stage renal disease. J. Am. Soc. Nephrol. 2004 15 7 1943 1951 10.1097/01.ASN.0000129337.50739.48 15213285
    [Google Scholar]
15. Chou F.F. Chen J.B. Huang S.C. Chan Y.C. Chi S.Y. Chen W.T. Changes in serum FGF23 and Klotho levels and calcification scores of the abdominal aorta after parathyroidectomy for secondary hyperparathyroidism. Am. J. Surg. 2019 218 3 609 612 10.1016/j.amjsurg.2018.12.026 30594298
    [Google Scholar]
16. Hou Y.C. Lu C.L. Zheng C.M. The role of vitamin D in modulating mesenchymal stem cells and endothelial progenitor cells for vascular calcification. Int. J. Mol. Sci. 2020 21 7 2466 10.3390/ijms21072466 32252330
    [Google Scholar]
17. Miskulin D.C. Majchrzak K. Tighiouart H. Ergocalciferol supplementation in hemodialysis patients with vitamin D deficiency: A randomized clinical trial. J. Am. Soc. Nephrol. 2016 27 6 1801 1810 10.1681/ASN.2015040468 26677862
    [Google Scholar]
18. Rodríguez M. Goodman W.G. Liakopoulos V. Messa P. Wiecek A. Cunningham J. The use of calcimimetics for the treatment of secondary hyperparathyroidism: A 10 year evidence review. Semin. Dial. 2015 28 5 497 507 10.1111/sdi.12357 25752650
    [Google Scholar]
19. Sevva C. Divanis D. Tsinari A. Pharmaceutical management of secondary hyperparathyroidism and the role of surgery: A 5-year retrospective study. Medicina 2024 60 5 812 10.3390/medicina60050812 38792994
    [Google Scholar]
20. Raggi P. Chertow G.M. Torres P.U. The ADVANCE study: A randomized study to evaluate the effects of cinacalcet plus low-dose vitamin D on vascular calcification in patients on hemodialysis. Nephrol. Dial. Transplant. 2011 26 4 1327 1339 10.1093/ndt/gfq725 21148030
    [Google Scholar]
21. Chertow G.M. Block G.A. Correa-Rotter R. Effect of cinacalcet on cardiovascular disease in patients undergoing dialysis. N. Engl. J. Med. 2012 367 26 2482 2494 10.1056/NEJMoa1205624 23121374
    [Google Scholar]
22. ter Braake A.D. Shanahan C.M. de Baaij J.H.F. Magnesium counteracts vascular calcification: Passive interference or active modulation? Arterioscler. Thromb. Vasc. Biol. 2017 37 8 1431 1445 10.1161/ATVBAHA.117.309182 28663256
    [Google Scholar]
23. Bressendorff I. Hansen D. Schou M. Pasch A. Brandi L. The effect of increasing dialysate magnesium on serum calcification propensity in subjects with end stage kidney disease: A randomized, controlled clinical trial. Clin. J. Am. Soc. Nephrol. 2018 13 9 1373 1380 10.2215/CJN.13921217 30131425
    [Google Scholar]
24. Roumeliotis S. Dounousi E. Salmas M. Eleftheriadis T. Liakopoulos V. Vascular calcification in chronic kidney disease: The role of vitamin K-dependent matrix Gla protein. Front. Med. 2020 7 154 10.3389/fmed.2020.00154 32391368
    [Google Scholar]
25. Price P.A. Faus S.A. Williamson M.K. Warfarin causes rapid calcification of the elastic lamellae in rat arteries and heart valves. Arterioscler. Thromb. Vasc. Biol. 1998 18 9 1400 1407 10.1161/01.ATV.18.9.1400 9743228
    [Google Scholar]
26. Fusaro M. Tripepi G. Noale M. Prevalence of vertebral fractures, vascular calcifications, and mortality in warfarin treated hemodialysis patients. Curr. Vasc. Pharmacol. 2015 13 2 248 258 10.2174/15701611113119990146 23927679
    [Google Scholar]
27. Krüger T. Oelenberg S. Kaesler N. Warfarin induces cardiovascular damage in mice. Arterioscler. Thromb. Vasc. Biol. 2013 33 11 2618 2624 10.1161/ATVBAHA.113.302244 23990204
    [Google Scholar]
28. Naiyarakseree N. Phannajit J. Naiyarakseree W. Effect of Menaquinone-7 supplementation on arterial stiffness in chronic hemodialysis patients: A multicenter randomized controlled trial. Nutrients 2023 15 11 2422 10.3390/nu15112422 37299386
    [Google Scholar]
29. Saritas T. Reinartz S. Krüger T. Vitamin K1 and progression of cardiovascular calcifications in hemodialysis patients: The VitaVasK randomized controlled trial. Clin. Kidney J. 2022 15 12 sfac184 10.1093/ckj/sfac184 37216675
    [Google Scholar]
30. De Vriese A.S. Caluwé R. Pyfferoen L. Multicenter randomized controlled trial of vitamin K antagonist replacement by rivaroxaban with or without vitamin K2 in hemodialysis patients with atrial fibrillation: The Valkyrie Study. J. Am. Soc. Nephrol. 2020 31 1 186 196 10.1681/ASN.2019060579 31704740
    [Google Scholar]
31. Levy-Schousboe K. Frimodt-Møller M. Hansen D. Vitamin K supplementation and arterial calcification in dialysis: Results of the double-blind, randomized, placebo-controlled RenaKvit trial. Clin. Kidney J. 2021 14 9 2114 2123 10.1093/ckj/sfab017 34476095
    [Google Scholar]
32. Oikonomaki T. Papasotiriou M. Ntrinias T. The effect of vitamin K2 supplementation on vascular calcification in haemodialysis patients: A 1-year follow-up randomized trial. Int. Urol. Nephrol. 2019 51 11 2037 2044 10.1007/s11255‑019‑02275‑2 31529295
    [Google Scholar]
33. Haroon S. Davenport A. Ling L.H. Randomized controlled clinical trial of the effect of treatment with vitamin K2 on vascular calcification in hemodialysis patients (Trevasc-HDK). Kidney Int. Rep. 2023 8 9 1741 1751 10.1016/j.ekir.2023.06.011 37705910
    [Google Scholar]
34. Nigwekar S.U. Thadhani R. Brandenburg V.M. Calciphylaxis. N. Engl. J. Med. 2018 378 18 1704 1714 10.1056/NEJMra1505292 29719190
    [Google Scholar]
35. Raggi P. Bellasi A. Bushinsky D. Slowing progression of cardiovascular calcification with SNF472 in patients on hemodialysis: Results of a randomized phase 2b study. Circulation 2020 141 9 728 739 10.1161/CIRCULATIONAHA.119.044195 31707860
    [Google Scholar]
36. Djuric P. Dimkovic N. Schlieper G. Sodium thiosulphate and progression of vascular calcification in end-stage renal disease patients: A double-blind, randomized, placebo-controlled study. Nephrol. Dial. Transplant. 2020 35 1 162 169 10.1093/ndt/gfz204 31764989
    [Google Scholar]
37. Chen C.L. Chen N.C. Wu F.Z. Wu M.T. Impact of denosumab on cardiovascular calcification in patients with secondary hyperparathyroidism undergoing dialysis: A pilot study. Osteoporos. Int. 2020 31 8 1507 1516 10.1007/s00198‑020‑05391‑3 32246167
    [Google Scholar]